• Home
  • Meet Your Attorney
  • Intellectual Property
    • Copyright Protection
    • Trade Secrets and Unfair Competition
    • Patents
    • Trademarks
  • Business Law
    • Asset Purchase Agreements
    • Business Formations
    • Business Plans
    • Consulting Agreements
    • Licensing and Negotiation
    • Non-Disclosure and Non-Compete Agreement
  • Alternative Dispute Resolution
  • Featured Clients
    • Nitroponics
    • Cukoo Nest Art Studio
    • The Locals Mix
    • Teresa Rand Consulting
    • Censys Technologies
    • Oogaa
    • Crisbee
    • Epic Axe Throwing
    • Xena Intelligent Security
    • Pizzamico
    • Kimberly Faith
    • Illumin8er
  • News
    • Office Moving 08.08.20
    • Copyright Fees 03.17.20
    • TikTok Blockchain 03.17.20
    • Skidmore V. Zeppelin 03.17.20
    • SCORE 02.18.2020
    • IP Gender Pay Gap 02.04.2020
    • Trade US and China 01.21.2020
    • Sandman Super Lawyers 09.24.2019
    • Skidmore V. Zeppelin 09.24.2019
    • The Slants 09.24.2019
    • Costly Patents 05.28.2019
    • Sandman Law Philly 05.28.2019
    • SCORE 04.16.2019
    • Section Meeting Volusia 04.16.2019
    • Sandman Middle District 02.12.2019
    • Women Inventors 02.12.2019
    • Electronic Revival 12.20.2018
  • Contact Us

Changes in Intellectual Property: Trade Deal between United States and China

The United States and China entered into a historic treaty this month, focusing much-needed attention to the problems of trade inequity and intellectual property protection. The Economic and Trade Agreement between the Government of the United States of America and the Government of the People’s Republic of China (Link) was signed January 15, 2020. The signing of Phase 1 of this trade deal between the two countries brings new rules for commerce and intellectual property dealings aimed at equity and security in these crucial business areas.
One of the major impacts expected from the agreement is in regulations affecting duration of pharmaceutical patent protection within China. The agreement extends patent protection in China for certain patents to make up for lost market time due to delays from the patent office and Chinese health regulators. Pharmaceutical patent disputes in China are now subject to a process involving blocking sales of potential copycat medicine until all disputes are resolved, similar to the automatic 30-month block of regulatory approval in the United States during a pharmaceutical patent dispute. These changes aim to incentivize companies to conduct more research and protect current medications in development within China.
More information on this can be found here:
“China Agrees to Tweaks on Drug Patents as Part of Trade Deal”, https://www.bloomberg.com/news/articles/2020-01-15/china-agrees-to-changes-on-drug-patents-as-part-of-trade-deal “Trump Signs ‘Phase 1’ China Trade Deal, But Most Tariffs Remain In Place”, https://www.npr.org/2020/01/15/796305300/trump-to-sign-phase-one-china-trade-deal-but-most-tariffs-remain-in-place

Contact
386-206-2898
Info@sandmanip.com
Address
125 Basin Street, Suite 206 Daytona Beach, FL 32114
© 2021 Sandman Law Office, PLLC

We use cookies to enable essential functionality on our website, and analyze website traffic. By clicking Accept you consent to our use of cookies. Read about how we use cookies.

Your Cookie Settings

We use cookies to enable essential functionality on our website, and analyze website traffic. Read about how we use cookies.

Cookie Categories

Essential

These cookies are strictly necessary to provide you with services available through our websites. You cannot refuse these cookies without impacting how our websites function. You can block or delete them by changing your browser settings, as described under the heading "Managing cookies" in the Privacy and Cookies Policy.

Analytics

These cookies collect information that is used in aggregate form to help us understand how our websites are being used or how effective our marketing campaigns are.